• Verona announces positive results for DPI form of COPD drug pharmaceutical-technology
    August 06, 2019
    UK-based Verona Pharma have announced the dry powdered inhaler (DPI) formulation of ensifentrine for chronic obstructive pulmonary disorder (COPD) has achieved all the endpoints in a Phase II trial.
  • NICE approves AstraZeneca’s COPD drug europeanpharmaceuticalreview
    July 04, 2017
    The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
PharmaSources Customer Service